1 lysis patients, including those positive for hepatitis C antibody.

2 ceiving a renal transplant were positive for hepatitis C antibodies.

3 risk drug-using practices, as was found with hepatitis C antibodies.

4 containing the non-specific Ab (anti-HCV for Hepatitis C) antibodies.

5             Among those testing positive for hepatitis C antibody, 78% either had a transfusion or ha

6 study was to estimate the prevalence of anti-hepatitis C antibody and evaluate factors associated wit

7       The corresponding odds ratio comparing hepatitis C antibodies (HCV Ab) (+) to HCV Ab (-) partic

8 se of hepatitis B core antibody (HBcAb+) and hepatitis C antibody (HCV Ab+) positive donors represent

9                               Tests included hepatitis C antibody, HCV RNA, HCV genotype (nucleic aci

10 NA level, lower pretreatment CD4 cell count, hepatitis C antibody, less education, and recent nonadhe

11 ansplantation compared with patients who are hepatitis C antibody negative.

12 e, suffered brain death secondary to trauma, hepatitis C antibody-negative, not categorized as high r

13 ce, more amino acid mixtures (all P < .001), hepatitis C antibody negativity (P = .05), and black rac

14          Renal transplant recipients who are hepatitis C antibody positive do not have an increased r

15 line medical condition, diagnosis, and donor hepatitis C antibody status impacted 1- and 5-year survi

16 d models were used to evaluate the impact of hepatitis C antibody status on the study endpoints.

17 om a cohort of real-world patients receiving hepatitis C antibody therapy with LDF/SOF +/- RBV suppor